Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

This is a prospective, single-center, single-arm Phase II clinical study designed to investigate the efficacy and safety of vebreltinib combined with platinum-based chemotherapy in treatment-naïve patients with driver gene-negative, locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET overexpression.In this study, all eligible participants will provide written informed consent, and after meeting the inclusion and exclusion criteria during screening, will receive vebreltinib (150 mg orally Bid) plus platinum-doublet chemotherapy. Oral vebreltinib (150 mg Bid) will be continued until disease progression or unacceptable toxicity.